1. Scrip
  2. >>New Products

Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category

 
• By Jessica Merrill

Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.

set sail
Arcutis has set sail on its first commercial launch • Source: Shutterstock

Arcutis Biotherapeutics, Inc. is launching its first commercial drug, Zoryve (roflumilast), a topical cream approved by the US Food and Drug Administration on 29 July for plaque psoriasis, joining a newly competitive category for non-steroidal topical drugs.

The approval of Zoryve follows closely on the heels of the launch of Dermavant Sciences Inc.'s Vtama (tapinarof), another topical cream for psoriasis. The two drugs work through different mechanisms and have differences but will be targeting the same market as new non-steroidal alternatives for patients with plaque psoriasis. Vtama was approved by the FDA in May and is also the Roivant-owned company's first commercial launch

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.